How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation

John P.A. Ioannidis, Y S Betty Kim, Alan Trounson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The clinical translation of promising products, technologies and interventions from the disciplines of nanomedicine and cell therapy has been slow and inefficient. In part, translation has been hampered by suboptimal research practices that propagate biases and hinder reproducibility. These include the publication of small and underpowered preclinical studies, suboptimal study design (in particular, biased allocation of experimental groups, experimenter bias and lack of necessary controls), the use of uncharacterized or poorly characterized materials, poor understanding of the relevant biology and mechanisms, poor use of statistics, large between-model heterogeneity, absence of replication, lack of interdisciplinarity, poor scientific training in study design and methods, a culture that does not incentivize transparency and sharing, poor or selective reporting, misaligned incentives and rewards, high costs of materials and protocols, and complexity of the developed products, technologies and interventions. In this Perspective, we discuss special manifestations of these problems in nanomedicine and in cell therapy, and describe mitigating strategies. Progress on reducing bias and enhancing reproducibility early on ought to enhance the translational potential of biomedical findings and technologies.

Original languageEnglish (US)
Pages (from-to)797-809
Number of pages13
JournalNature Biomedical Engineering
Volume2
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Nanomedicine
Medical nanotechnology
Cell- and Tissue-Based Therapy
Technology
Biomedical Technology
Reward
Publications
Motivation
Costs and Cost Analysis
Transparency
Research
Statistics
Costs

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Computer Science Applications

Cite this

How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation. / Ioannidis, John P.A.; Kim, Y S Betty; Trounson, Alan.

In: Nature Biomedical Engineering, Vol. 2, No. 11, 01.11.2018, p. 797-809.

Research output: Contribution to journalArticle

@article{1f8662eed00c41589bbf82198d22bb98,
title = "How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation",
abstract = "The clinical translation of promising products, technologies and interventions from the disciplines of nanomedicine and cell therapy has been slow and inefficient. In part, translation has been hampered by suboptimal research practices that propagate biases and hinder reproducibility. These include the publication of small and underpowered preclinical studies, suboptimal study design (in particular, biased allocation of experimental groups, experimenter bias and lack of necessary controls), the use of uncharacterized or poorly characterized materials, poor understanding of the relevant biology and mechanisms, poor use of statistics, large between-model heterogeneity, absence of replication, lack of interdisciplinarity, poor scientific training in study design and methods, a culture that does not incentivize transparency and sharing, poor or selective reporting, misaligned incentives and rewards, high costs of materials and protocols, and complexity of the developed products, technologies and interventions. In this Perspective, we discuss special manifestations of these problems in nanomedicine and in cell therapy, and describe mitigating strategies. Progress on reducing bias and enhancing reproducibility early on ought to enhance the translational potential of biomedical findings and technologies.",
author = "Ioannidis, {John P.A.} and Kim, {Y S Betty} and Alan Trounson",
year = "2018",
month = "11",
day = "1",
doi = "10.1038/s41551-018-0314-y",
language = "English (US)",
volume = "2",
pages = "797--809",
journal = "Nature Biomedical Engineering",
issn = "2157-846X",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation

AU - Ioannidis, John P.A.

AU - Kim, Y S Betty

AU - Trounson, Alan

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The clinical translation of promising products, technologies and interventions from the disciplines of nanomedicine and cell therapy has been slow and inefficient. In part, translation has been hampered by suboptimal research practices that propagate biases and hinder reproducibility. These include the publication of small and underpowered preclinical studies, suboptimal study design (in particular, biased allocation of experimental groups, experimenter bias and lack of necessary controls), the use of uncharacterized or poorly characterized materials, poor understanding of the relevant biology and mechanisms, poor use of statistics, large between-model heterogeneity, absence of replication, lack of interdisciplinarity, poor scientific training in study design and methods, a culture that does not incentivize transparency and sharing, poor or selective reporting, misaligned incentives and rewards, high costs of materials and protocols, and complexity of the developed products, technologies and interventions. In this Perspective, we discuss special manifestations of these problems in nanomedicine and in cell therapy, and describe mitigating strategies. Progress on reducing bias and enhancing reproducibility early on ought to enhance the translational potential of biomedical findings and technologies.

AB - The clinical translation of promising products, technologies and interventions from the disciplines of nanomedicine and cell therapy has been slow and inefficient. In part, translation has been hampered by suboptimal research practices that propagate biases and hinder reproducibility. These include the publication of small and underpowered preclinical studies, suboptimal study design (in particular, biased allocation of experimental groups, experimenter bias and lack of necessary controls), the use of uncharacterized or poorly characterized materials, poor understanding of the relevant biology and mechanisms, poor use of statistics, large between-model heterogeneity, absence of replication, lack of interdisciplinarity, poor scientific training in study design and methods, a culture that does not incentivize transparency and sharing, poor or selective reporting, misaligned incentives and rewards, high costs of materials and protocols, and complexity of the developed products, technologies and interventions. In this Perspective, we discuss special manifestations of these problems in nanomedicine and in cell therapy, and describe mitigating strategies. Progress on reducing bias and enhancing reproducibility early on ought to enhance the translational potential of biomedical findings and technologies.

UR - http://www.scopus.com/inward/record.url?scp=85056256649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056256649&partnerID=8YFLogxK

U2 - 10.1038/s41551-018-0314-y

DO - 10.1038/s41551-018-0314-y

M3 - Article

C2 - 30931172

AN - SCOPUS:85056256649

VL - 2

SP - 797

EP - 809

JO - Nature Biomedical Engineering

JF - Nature Biomedical Engineering

SN - 2157-846X

IS - 11

ER -